Amylyx Pharmaceuticals (NASDAQ:AMLX) Issues Earnings Results, Misses Estimates By $0.03 EPS

Amylyx Pharmaceuticals (NASDAQ:AMLX) announced its quarterly earnings results on Thursday. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.03), FiscalAI reports.

Here are the key takeaways from Amylyx Pharmaceuticals’ conference call:

• LUCIDITY top-line data is expected in late August or early September 2026 after the final participant completed the 16-week study period; database cleaning and locking are still underway, and management remains blinded to the results.
• Amylyx reported $250.8 million in cash and marketable securities at quarter-end and expects its cash runway to extend into 2028, covering anticipated avexitide milestones, including a potential 2027 launch.
• Commercial preparations are advancing ahead of a potential avexitide approval, including field medical deployment, key commercial hires, an HCP and patient education campaign, and plans to target treatment centers with concentrated PBH populations.
• Management estimates approximately 160,000 U.S. patients have post-bariatric hypoglycemia and cites high endocrinologist intent to treat with an approved therapy; a dedicated ICD-10 code becomes effective October 1, 2026, potentially improving recognition and tracking of the condition.
• Q2 operating expenses rose 7% year over year to $45.7 million, driven partly by higher legal costs, including a one-time charge, and increased commercial investment; avexitide’s approval, label breadth, and launch timing remain dependent on the pending phase III data and FDA review.

Amylyx Pharmaceuticals Stock Performance

NASDAQ AMLX traded down $1.37 during trading on Friday, reaching $22.82. The company’s stock had a trading volume of 2,678,272 shares, compared to its average volume of 1,419,705. The business’s fifty day moving average price is $17.19 and its 200-day moving average price is $15.71. Amylyx Pharmaceuticals has a twelve month low of $7.48 and a twelve month high of $24.60. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -15.21 and a beta of -0.21.

Analyst Ratings Changes

Several brokerages have recently issued reports on AMLX. Citigroup upped their target price on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the company a “buy” rating in a report on Monday. Wall Street Zen lowered shares of Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Mizuho boosted their price target on shares of Amylyx Pharmaceuticals from $21.00 to $24.00 and gave the company an “outperform” rating in a research report on Monday, July 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a research note on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $34.00 price objective on shares of Amylyx Pharmaceuticals in a report on Monday, June 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Amylyx Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $25.38.

Insider Buying and Selling at Amylyx Pharmaceuticals

In related news, insider Gina Mazzariello sold 15,000 shares of the firm’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the transaction, the insider owned 194,090 shares of the company’s stock, valued at $3,555,728.80. This trade represents a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 10.90% of the company’s stock.

Institutional Trading of Amylyx Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the stock. Meeder Asset Management Inc. acquired a new position in Amylyx Pharmaceuticals during the 4th quarter worth approximately $25,000. California State Teachers Retirement System purchased a new position in shares of Amylyx Pharmaceuticals during the 2nd quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Amylyx Pharmaceuticals by 1,116.9% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,454 shares of the company’s stock valued at $54,000 after buying an additional 4,088 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Amylyx Pharmaceuticals by 433.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 7,267 shares of the company’s stock valued at $47,000 after buying an additional 5,904 shares during the period. Finally, Legal & General Group Plc purchased a new stake in shares of Amylyx Pharmaceuticals in the second quarter valued at approximately $47,000. 95.84% of the stock is owned by institutional investors and hedge funds.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.